BioCentury

8:00 AM GMT, Feb 6, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Product Development

Specifying stroke

Thrombolytic Science International LLC is developing a combination product to target only the clots that lead to stroke, which it expects will significantly reduce bleeding and potentially double the treatment window compared with the only drug approved for the indication.

The company, which was founded in 2006 but emerged from stealth mode in January, is developing a mutated version of pro-urokinase. Urokinase is a serine protease that activates plasminogen to start the proteolysis cascade, leading to clot thrombolysis.

Because

Read the full 770 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.